Insulet Corp (STU:GOV)
€ 228.1 5 (2.24%) Market Cap: 17.41 Bil Enterprise Value: 17.87 Bil PE Ratio: 45.89 PB Ratio: 16.81 GF Score: 93/100

Insulet Corp at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 05:45PM GMT
Release Date Price: €184.55 (+0.63%)
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Hi, I'm Robbie Marcus, I'm the medtech analyst at JPMorgan. Really happy to introduce our next speaker, Jim Hollingshead from Insulet, the CEO. Jim, let you do the presentation, then I'll come up on stage. We'll do a little Q&A.

James R. Hollingshead
Insulet Corporation - President, CEO & Director

Perfect. Good morning, everybody. Thank you, Robbie, and thanks for the opportunity. Glad to have the opportunity to talk with you all the day and glad you're all here. So thank you for coming. I want to start by introducing you to Kimsue here on our cover page. Kimsue is a digital creator. She's a stylist and an influencer and she was diagnosed with Type 1 diabetes more than a decade ago. And she's been using Omnipod 5, our flagship product since last year, just in the last year.

And Kimsue loves this product. She tells us she's very active. She's doing things all the time. And what she tells us is that Omnipod 5 allows people with Type 1 diabetes to fly like she does. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot